Retatrutide
Profilo del Composto

Retatrutide

Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease

Noto anche come: LY3437943 · triple agonist peptide · GLP-1/GIP/glucagon receptor agonist

Photo on Pexels

Chemistry data
Class
triple incretin receptor agonist (GLP-1/GIP/glucagon)
Sequence
Not publicly disclosed (proprietary Eli Lilly peptide)
Half-life
approximately 6 days (enabling once-weekly dosing)
Routes
subcutaneous
Studied doses
subcutaneous 1 mg, 4 mg, 8 mg, or 12 mg once weekly · subcutaneous 0.5 mg to 12 mg once weekly

Stato Normativo

Stati Uniti
investigational
Unione Europea
research_only
Regno Unito
research_only

Come funziona

  • GLP-1 receptor agonism enhancing insulin secretion, suppressing glucagon release, and promoting satiety through central nervous system pathways
  • GIP receptor agonism augmenting insulinotropic effects and potentially improving lipid metabolism and adipose tissue function
  • Glucagon receptor agonism stimulating hepatic fatty acid oxidation, increasing energy expenditure, and promoting lipolysis
  • Synergistic triple receptor activation producing greater weight loss than single or dual agonism through complementary metabolic pathways

Risultati della ricerca

Contesto di dosaggio

  • Vie di Somministrazione
    subcutaneous
    Intervallo
    1 mg, 4 mg, 8 mg, or 12 mg once weekly

    Phase 2 clinical trials for obesity (escalation from 0.5 mg to target dose over 4-8 weeks)

  • Vie di Somministrazione
    subcutaneous
    Intervallo
    0.5 mg to 12 mg once weekly

    Phase 2 clinical trials for type 2 diabetes (various escalation regimens)

🧮 Reconstitution Calculator

Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.

Open Calculator →

Effetti collaterali: contesto di ricerca

  • nausea (most common, typically mild to moderate)
  • diarrhea
  • vomiting
  • constipation
  • decreased appetite
  • abdominal pain
  • injection site reactions

Il riassunto completo della ricerca arriverà presto. Nel frattempo, consulta i dati scientifici e i riferimenti PubMed sopra.

Pagine Correlate